Ocular Therapeutix, Inc.
OCUL · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $2 | $2 | $1 | $1 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $2 | $1 | $1 | $1 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 8.1% | 25.8% | -37.4% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 87.8% | 85.6% | 88.2% | 92.8% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -449.3% | -473.8% | -561.7% | -259.5% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -477.3% | -503.9% | -598.7% | -283.3% |
| EPS Diluted | -0.38 | -0.39 | -0.38 | -0.29 |
| % Growth | 2.6% | -2.6% | -31% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |